==Core Scientific (CORZ) to be acquired by CoreWeave (CRWV)

 

CoreWeave to acquire Core Scientific (CORZ) in an all-stock transaction implying a total equity value of $9 bln, expected to close in the fourth quarter of 2025 

• Under the terms of the merger agreement, Core Scientific (CORZ) stockholders will receive 0.1235 newly issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock based on a fixed exchange ratio.
• Following CoreWeave's successful IPO in March 2025, this acquisition will help CoreWeave verticalize its data center footprint to future-proof revenue growth and enhance profitability.
• Through this acquisition, CoreWeave will own approximately 1.3 GW of gross power across Core Scientific's national data center footprint1 with an incremental 1 GW+ of potential gross power available for expansion.
• As of July 3, 2025, the agreed-upon exchange ratio implies a total equity value of approximately $9.0 billion.
• This is calculated on a fully diluted basis and based on CoreWeave's 5-day VWAP. This represents a $20.40 per share value based on the closing price of CoreWeave Class A common stock as of July 3, 2025, and a premium of approximately 66% to the unaffected Core Scientific closing share price of $12.30 on June 25, 2025.
• The final value will be determined at the time of transaction close.
• Upon close, CoreWeave expects Core Scientific's stockholders' ownership of the combined company will be less than 10%.

Omada Health prices IPO at $19 per share

• Omada Health is set to start trading on the Nasdaq under the ticker symbol “OMDA.”
• It’s the second digital health company to hit the market in a matter of weeks, following Hinge Health’s debut in May.
• The company priced its IPO at $19 a share.

Omada Health is a virtual-first healthcare provider focused on helping individuals manage and improve their health, especially those with chronic conditions like prediabetes, diabetes, hypertension, and musculoskeletal issues. 

The virtual chronic care company said in a press release that 7.9 million shares are being sold in the offering, amounting to $150 million.

Omada, founded in 2012, will trade on the Nasdaq under the ticker symbol “OMDA.” The company filed its initial prospectus in May and updated the document with an expected pricing range of $18 to $20 per share. 

At the IPO price, Omada is worth about $1.1 billion, though that number could be higher on a fully diluted basis. That’s right around its private market valuation from 2022, when Omada announced a $192 million funding round that pushed its valuation above $1 billion.

U.S. Venture Partners, Andreessen Horowitz and Fidelity’s FMR LLC are the largest outside shareholders in the company, each owning between 9% and 10% of the stock.

Circle Internet Group (CRCL) began trading on the NYSE on Thur 5 June 25

Circle Internet Group (CRCL) had a wildly successful debut. After pricing its IPO at $31.00 per share, the global fintech specializing in stablecoins traded as high as $103.75 before closing the session at 83.23.

• Opened at $69 after pricing IPO at $31/share

 

 

• Circle Internet Group (CRCL) is stormed out of the gate as its upsized 34.0 mln share IPO priced at $31/share, above the expected range of $27-$28, achieving a market valuation of $6.9 bln ($8.1 bln fully diluted). Shares opened at $69, a 122.6% surge, reflecting extraordinary investor demand. The IPO raised $1.054 bln in gross proceeds, significantly exceeding the initial target of $624 mln.
• CRCL is a global fintech specializing in stablecoins, notably USD Coin (USDC), the second-largest stablecoin with a $62 bln market capitalization, trailing only Tether's USDT. USDC, pegged 1:1 to the U.S. dollar, facilitates low-cost, rapid cross-border transactions and serves as a trading and DeFi collateral asset. Circle generates revenue primarily through reserve income, transaction and treasury services, and partnerships. In regard to partnerships, CRCL has a 50% revenue sharing agreement with Coinbase (COIN), a key USDC distributor.
• CRCL's mission is to foster a secure, efficient digital dollar ecosystem, bridging traditional finance and blockchain for payments, commerce, and financial applications. Its regulatory compliance, including a 2015 New York BitLicense, positions it as a trusted player for institutional adoption.
• The company's growth prospects are tied to the expanding stablecoin market, projected to grow as digital payments and DeFi gain traction. USDC's ~25% market share and $62 bln in circulation position it to capture increasing demand for stable, blockchain-based transactions, particularly in cross-border payments and B2B use cases. The pending U.S. stablecoin bill, supported by the Trump administration's pro-crypto stance, could enhance USDC's legitimacy and institutional adoption, though it may invite competition from banks exploring their own stablecoins.
• In 2024, CRCL reported revenue and reserve income of $1.68 bln, a 16.1% yr/yr increase, driven by a 9% increase in average daily USDC in circulation reflecting increased demand for Circle stablecoins related to digital asset trading activity, market share gains as it continues to grow in key markets, as well as expanded strategic partnerships and integrations. However, net income fell 41.8% to $(111.9) mln, reflecting rising costs. Distribution and transaction expenses jumped 40.4% in FY24, outpacing revenue growth, due to COIN's revenue-sharing agreement and third-party distribution costs.

Kymera Therapeutics (KYMR) : atopic dermatitis potential matches Sanofi/Regeneron's blockbuster Dupixent in early biomarker response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.

The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 208
• Founded by Bruce Lee Booth and Nello Mainolfi in September 2015 
• Headquartered in Watertown, Massachusetts
• https://www.kymeratx.com

IPO: Aug 21, 20

 

 

 

 

Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. 

Edible Garden (EDBL) : 3-year performance

 

 

 

==NeurAxis (NRXS) : FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms

CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim™ for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is the second successful expanded FDA indication for IB-Stim, following its initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS). The new indication represents the first treatment ever cleared or approved by the FDA related to functional dyspepsia. It is expected to nearly double the Company’s total addressable market, reinforcing NeurAxis’ leadership in non-invasive, pediatric-focused neuromodulation.

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

US IPO Weekly Recap

Four IPOs and six SPACs debuted this week.  

Global trading platform eToro Group (ETOR) priced its upsized US IPO above the range to raise $620 million at a $4.9 billion market cap. eToro’s platform aims to combine a social network with the ability to trade and invest, all within a regulated, digital investment platform for financial discourse. As of December 31, 2024, eToro had approximately 3.5 million Funded Accounts across its global footprint of 75 countries. The company’s total commission grew 45% in 2024, and its net contribution grew 41%. However, it is dependent on volatile trading volumes and prices, and is subject to varying regulations, especially within the crypto space. eToro finished the week up 23%.

Singapore-based digital asset-focused financing firm Antalpha Platform Holding (ANTA) priced its US IPO at the top of the range to raise $49 million at a $329 million market cap. Antalpha provides financing, technology, and risk management solutions to the digital asset industry. The company is the primary lending partner for Bitmain and provides supply chain financing solutions to institutional and corporate participants in the Bitcoin mining industry, offering loans secured by Bitcoin and Bitcoin mining machines. Its revenue jumped more than three times in 2024, although it demands on volatile crypto demand and prices. It finished the week down 6%.

Singapore-based oil and gas equipment maker OMS Energy Technologies (OMSE) priced its downsized US IPO at the midpoint to raise $33 million at a $382 million market cap. The company manufactures surface wellhead systems and oil country tubular goods, primarily for onshore and offshore E&P activities. OMS has a 10-year agreement with Saudi Aramco, which accounts for a majority of the company’s revenue. It finished the week down 13%.

Autonomous delivery systems developer Arrive AI (ARAI) completed its direct listing this week. Arrive AI is developing autonomous last mile mailboxes, designed to support deliveries done by robots and drones. Arrive AI is also developing a suite of software and services for its mailboxes, including features for scheduling, space optimization, and notifications. The company is in the development stage, and has generated no revenues to date. Its finished the week down 21%.

Six SPACs listed this week. Churchill Capital X (CCCXU), founded by former Citi executive Michael Klein, raised $360 million. Wen Acquisition (WENNU) raised $261 million to target fintech and blockchain. Cohen & Company-backed Columbus Circle Capital I (CCCMU) raised $220 million. Renatus Tactical Acquisition (RTACU), led by the former CEO of Digital World Acquisition, raised $210 million to target tech. Perimeter Acquisition I (PMTRU) raised $210 million to target defense and national security. Thayer Venture Acquisition II (TVAIU), the second blank check company formed by Thayer Ventures, raised $175 million to target travel and transportation.

Life360 (LIF) reported earnings on Mon 12 May 25 (a/h)

 Life360 provides technology for tracking family, pets and valuables. The company sells Tile-brand tracking devices.

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 455
• Incorporated in 2007
• Headquartered in San Mateo, California
• https://intl.life360.com 

ticker: LIF

 ** charts after earnings **

ticker: LIF

IPO: June 6, 2024

Life360 (LIF) — a provider of tracking services for family, pets and valuables — late Monday beat Wall Street's revenue estimate for the first quarter but came up short on total users. Its full-year sales guidance also was light. Life360 stock fell in extended trading.

The San Mateo, Calif.-based company said it earned 5 cents a share on sales of $103.6 million in the March quarter. In the year-earlier period, it lost 14 cents a share on sales of $78.2 million. Analysts polled by FactSet had expected sales of $101.4 million in the first quarter.

Life360 ended the period with 83.7 million global monthly active users, up 26% year over year. However, analysts were expecting 84.5 million.

The company also added 137,000 accounts to its subscription offering, ending the period with 2.4 million Paying Circles worldwide. A Paying Circle is a group of Life360 members with a paying subscription.

Life360 describes itself as a "family connection and safety company." It sells Tile-brand tracking devices and subscription services for families to keep track of loved ones and valuable items like purses, wallets, car keys and bikes.

Black Rifle Coffee Co. (BRCC) reported earnings on Mon 5 May 25 (a/h)

BRC Inc. operates as a veteran-controlled, non-alcoholic beverage company that uniquely blends high-quality coffee production with military and firearms-themed merchandise.

• Sector: Consumer Defensive
• Industry: Packaged Foods
• Full Time Employees: 551
• Founded in 2014 
• HQ in Salt Lake City, Utah
• https://www.blackriflecoffee.com

IPO: February 10, 2022 via a merger with a special purpose acquisition company, or SPAC, affiliate of SilverBox Capital

ticker: BRCC

 ** charts after earnings **

SALT LAKE CITY--(BUSINESS WIRE)--BRC Inc. (NYSE: BRCC), a Veteran-founded, mission-driven premium beverage company, today announced financial results for the first quarter of fiscal year 2025.

• In Q1 2025, packaged coffee distribution increased by 12.2 percentage points to 50.2% ACV and Ready-to-Drink ("RTD") coffee distribution grew by 5.1 percentage points to 47.9% ACV compared to Q1 2024.
• Wholesale revenue declined 6.0% compared to Q1 2024, primarily due to the net reduction of $8.5 million in prior-year barter transaction revenue.
• Net loss was $7.8 million in Q1 2025, a decrease of $9.7 million compared to net income of $1.9 million in Q1 2024. Adjusted EBITDA was $0.9 million, down $11.6 million from $12.5 million in Q1 2024.

IPOs this week : May 5 - 9, 25 (wk 19)

Aspen Insurance – Hamilton, Bermuda, 11 million shares, priced at $29-$31, managed by Goldman Citi. Proposed NYSE symbol AHL. Business: Bermuda-based global provider of specialty P&C insurance and reinsurance.

American Integrity – Tampa, Fla., 6.9 million shares, priced at $15-$17, managed by KBW Piper Sandler. Proposed NYSE symbol AII. Business: Florida-based provider of personal residential property insurance.

OMS Energy Technologies – Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Apimeds Pharmaceuticals – Hopewell, N.J., 3.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

Kandal M Venture – Takhmao, Cambodia, 2 million shares, priced at $4-$5, managed by Dominari Sec. Revere Sec.. Proposed Nasdaq symbol FMFC. Business: Cambodia-based contract manufacturer of affordable luxury leather goods.

AirSculpt Technologies (AIRS) reported earnings on Fri 2 May 25 (b/o)

AirSculpt Technologies provides custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.

• Sector: Healthcare
• Industry: Medical Care Facilities
• Full Time Employees: 389
• Founded by Aaron J. Rollins in 2012  
• Headquartered in Miami Beach, Florida
• https://airsculpt.com

Ticker: AIRS

** charts after earnings **

 

 

First Quarter 2025 Results

• Case volume was 3,076 for the first quarter of 2025, representing a 17.9% decline from the fiscal year 2024 first quarter case volume of 3,746;
• Revenue declined 17.3% to $39.4 million from $47.6 million in the fiscal year 2024 first quarter;
• Net loss for the quarter was $2.8 million compared to net income of $6.0 million in the fiscal year 2024 first quarter; and Adjusted EBITDA was $3.8 million compared to $7.3 million for the fiscal year 2024 first quarter.

2025 Outlook

The Company projects full year 2025 revenue and adjusted EBITDA guidance as follows:

• Revenues of approximately $160 to $170 million
• Adjusted EBITDA of approximately $16 to $18 million

IPOs this week : Apr 28 - May 2, 25 (wk 18)

AIRO - Albuquerque, N.M., 5 million shares, priced at $14-$16, managed by Cantor Fitz. BTIG. Proposed Nasdaq symbol AIRO. Business: Developer of drones and eVTOL aircraft.

OMS Energy Technologies - Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Bgin Blockchain - Singapore, 6.3 million shares, priced at $7-$9, managed by Chardan Benchmark. Proposed Nasdaq symbol BGIN. Business: Makes equipment for cryptocurrency mining with a focus on alternative coins.

Yuanbao - Beijing, 2 million shares, priced at $13-$15, managed by Goldman (Asia) Citi. Proposed Nasdaq symbol YB. Business: Online distributor of insurance policies in China.

Apimeds Pharmaceuticals – Hopewell, N.J., 3.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

==Skye Bioscience (SKYE) : 1-year performance

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. 

The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. 

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 16
• Headquartered in San Diego, California
• https://skyebioscience.com

CBLL : 6-month performance

Ticker: CBLL

Basel Medical Group (BMGL) began trading on the Nasdaq on Tue 25 Feb 25

Basel Medical Group Ltd engages in the provision of healthcare services in Singapore. 

• Sector: Healthcare
• Industry: Medical Care Facilities
• Full Time Employees: 32
• Incorporated in 2023 
• HQ in Singapore
• https://baselmedical.com

IPO: 25 Feb 25;  initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share

Ticker: BMGL

FatPipe (FATN) began trading on the Nasdaq on Tue 8 Apr 25

FatPipe, Inc. develops secure software-defined wide area network (SD-WAN), secure access service edge (SASE), and network monitoring service (NMS) software solutions for organizations in the United States and internationally.

Operations in the United States, Nigeria, Philippines, Australia, India, and South Africa.

• Sector: Technology
• Industry: Software - Infrastructure
• Full Time Employees: 154
• Founded in 1989
• HQ in Salt Lake City, Utah
• https://www.fatpipeinc.com

Ticker: FATN

Initial public offering of 695,656 shares of common stock at a public offering price of $5.75 per share.

 

Wellchange (WCT) : 6-month performance

Wellchange Holdings Co. Ltd. is a holding company, which engages in the provision of enterprise software solution services. It provides tailor-made software solutions, cloud-based software-as-a-service (SaaS) services, and white-labelled software design and development services. 

• Sector: Technology
• Industry: Software - Application
• Full Time Employees: 7
• Founded in 2011 
• Headquartered in Cheung Sha Wan, Hong Kong
• https://www.wchingtech.com

Stablecoin issuer Circle Internet Group, Inc. files for IPO

Circle, the company behind the USDC stablecoin, has filed for a U.S. initial public offering, becoming the latest tech firm that is aiming to test the market as tariff uncertainty and worries about the economy’s health weigh on the stockmarket.

In its prospectus filed with the Securities and Exchange Commission on Tuesday, Circle said it plans to list on the New York Stock Exchange under ticker symbol “CRCL.” A stablecoin is a cryptocurrency whose value is pegged, or tied, to that of another currency, commodity, or financial instrument and so tends to be less volatile than other digital assets like Bitcoin. USDC, which was launched in 2018, is backed by U.S. dollar assets.

Circle, which had previously announced plans to go public in 2021 via a SPAC merger, said in Tuesday's SEC filing that its net income last year was $155.7 million, down from $267.5 million a year earlier. It had $1.68 billion in revenue and reserve income in 2024, versus $1.45 billion in 2023.

Newsmax (NMAX) began trading on the NYSE on Mon 31 March 25

(Bloomberg) — Newsmax Inc.’s (NMAX) debut as a public company has given founder and Chief Executive Officer Christopher Ruddy a fortune of about $3.3 billion after its shares surged 735%.

Sector: Communication Services

Industry: Broadcasting

Full Time Employees: 400

https://invest.newsmax.com

Ticker: NMAX

The conservative cable news network sold $75 million of shares at $10 each in Monday’s initial public offering. The stock closed at $83.51 after repeated trading pauses due to volatility.

Ruddy’s 39.2 million class A shares, owned through a revocable trust, have 10 votes each, giving him control of 81% of the company’s votes. He didn’t sell any shares in the New York Stock Exchange offering.

Other investors include Interactive Brokers Group Inc. founder Thomas Peterffy, who owns 23 million shares worth $1.9 billion through Conyers Investments LLC; Sheikh Sultan bin Jassim Al-Thani, a Qatari royal whose investment firm, Heritage Advisors, owns 19.7 million shares; and Vadim Shulman, a Ukrainian industrialist.

Newsmax’s share price gives the company a market value of more than $10.7 billion. The Boca Raton, Florida-based firm lost $72 million last year on revenue of about $171 million. Fox Corp., which is worth almost $25 billion and operates competing network Fox News, reported net income of $2.4 billion on $6.5 billion of revenue in the same period.

Rupert Murdoch, who is chairman emeritus of Fox Corp., is worth $15.2 billion, according to the Bloomberg Billionaires Index.

ADMA Biologics (ADMA)

ADMA Biologics makes human-derived immunoglobulin. Its products treat people whose bodies don't make enough antibodies to ward off illnesses from common viruses. Instead of risking illness, people with primary immunodeficiency receive regular infusions of ADMA's drugs.

• Sector: Healthcare
• Industry: Biotechnology
• Full Time Employees: 685
• Founded by Adam S. Grossman and Jerrold B. Grossman in 2004  
• Headquartered in Ramsey, New Jersey
• https://www.admabiologics.com/

IPO: October 17, 2013

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. 

ADMA's biggest moneymaker, Asceniv. 

ADMA Biologics developed Asceniv in-house. It's a cocktail created from super donors whose plasma has a high level of antibodies capable of handling respiratory syncytial virus, or RSV. RSV leads to cold symptoms in most people, but it can be serious in people with compromised immune systems.

Last year, Asceniv generated $216.7 million in sales. This year, it's expected to bring in $283 million, growing almost 31%. Earnings are also promising. In 2024, ADMA Biologics earned 49 cents per share, flipping from no earnings in the year-earlier period. This year, it's expected to notch a 71-cent profit, up 45%.

Asceniv accounts for slightly more than half of ADMA's total sales. The company also sells Bivigam and Nabi-HB, two products it acquired. Bivigam provides various antibodies found in a healthy immune system, while Nabi-HB protects against hepatitis B in people who've been exposed.

 

eToro Group (NASDAQ: ETOR) has filed for a proposed IPO

Digital investment platform eToro filed for an initial public offering, saying it applied to list on the Nasdaq Global Select Market under the symbol ETOR.

• eToro’s net income grew to $192.4 million, compared with $15.3 million a year ago.

• The company, founded in 2007, provides trading and an investment platform to its customers.

The company said Monday its platform allows users to trade equities, currencies and commodities. The platform also allows users to trade crypto assets, with the company's co-founder and chief executive, Yoni Assia, saying the platform has helped millions of investors access the asset class in a safe way.

Spark Capital II, BRM Group, Andalusian SPV III, SBT Venture Fund I and CM SPC are listed among the company's principal shareholders.

Earlier this month, the company said it recently completed a $250 million funding round at a valuation of $3.5 billion. Investors in the funding round included ION Group and SoftBank Vision Fund 2, the company said.

EToro didn't provide an expected size for its IPO, nor did it offer an expected price range.

The company was founded in 2007 and said as of Dec. 31, 2024, it had about 3.5 million funded accounts.

IPOs this week : March 24 - 28, 25 (wk 13)

CoreWeave – Livingston, N.J., 49 million shares, priced at $47-$55, managed by Morgan Stanley JP Morgan. Proposed Nasdaq symbol CRWV. Business: Provides cloud computing services with data centers optimized for AI workloads.

OMS Energy Technologies – Singapore, 5.6 million shares, priced at $8-$10, managed by Roth Cap.. Proposed Nasdaq symbol OMSE. Business: Singapore-based manufacturer of surface wellhead systems and oil country tubular goods.

Bgin Blockchain – Singapore, 6.3 million shares, priced at $7-$9, managed by Chardan Benchmark. Proposed Nasdaq symbol BGIN. Business: Makes equipment for cryptocurrency mining with a focus on alternative currencies.

Apimeds Pharmaceuticals – Hopewell, N.J., 4.5 million shares, priced at $4-$5, managed by D. Boral Capital. Proposed NYSE American symbol APUS. Business: Clinical stage biotech developing bee venom-based treatment for inflammation.

Vantage – Singapore, 3.3 million shares, priced at $4-$5, managed by Network 1. Proposed NYSE American symbol VNTG. Business: Singapore-based shipbroking company focused on petroleum products.

FatPipe – Salt Lake City, .7 million shares, priced at $5.75-$7.75, managed by D. Boral Capital. Proposed Nasdaq symbol FATN. Business: Provides network software solutions for enterprises.

StubHub files for IPO

StubHub filed filed its initial public offering on Friday, revealing in the paperwork that revenues for 2024 jumped to $1.7 billion in 2024, a 30% increase over 2023 earnings.

The secondary market concert ticket vendor shares will be traded on the stock market under the ticket symbol STUB.

The company said in its filing that more than 40 million tickets were sold through StubHub in 2024, with transactions in 200 countries and territories involving more than 1 million sellers.

Nevertheless, StubHub reported a loss of $2.8 million for the year, quite a drop from the 405 million in profit it reported for 2023. Though according to the filing this is related to a rise in operational and sales and marketing expenses, extinguishment of debt, and related costs relative to 2023.

The company had planned to go public last year but withdrew in July.

The company launched in 2000 and for 13 years was a subsidiary of eBay, which acquired it in 2007 for $310 million. StubHub c0-founder Eric Baker bought the company back in 2020 in a $4 billion deal through his new company Viagogo.

European Wax Center (EWCZ) : 4-year performance

European Wax Center, Inc. operates as the franchisor and operator of out-of-home waxing services in the United States. It offers body and facial waxing services; and pre- and post-service products, including ingrown hair serums, exfoliating gels, brow shapers, and skin treatments, as well as skincare retail products. 

Q1 2025: 1,067 centers in 45 states.

• Sector: Consumer Defensive
• Industry: Household & Personal Products
• Full Time Employees: 124
• Founded in 2004 
• Headquartered in Plano, Texas
• https://waxcenter.com

IPO: August 5, 2021

Ticker: EWCZ

 

Ocugen (OCGN) : 10-year performance

Sector: Healthcare

Industry: Biotechnology

Founded: 2013

Headquarters: Malvern, Pennsylvania

Website: https://www.ocugen.com

Employees: 95

IPO: December 3, 2014

Ticker: OCGN

September 30, 2019: Ocugen (OCGN) completed a reverse merger with Histogenics (Nasdaq: HSGX), creating a company focused on developing therapies for ocular diseases, operating under the Ocugen name.